These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 14515715)

  • 1. [Immunological mechanisms of graft versus tumor effect].
    Ine S; Yamada M; Miyamura K; Sasaki T
    Nihon Rinsho; 2003 Sep; 61(9):1495-502. PubMed ID: 14515715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The allogeneic graft-versus-cancer effect.
    Ringdén O; Karlsson H; Olsson R; Omazic B; Uhlin M
    Br J Haematol; 2009 Dec; 147(5):614-33. PubMed ID: 19735262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y; Thoburn CJ; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cells require TRAIL for optimal graft-versus-tumor activity.
    Schmaltz C; Alpdogan O; Kappel BJ; Muriglan SJ; Rotolo JA; Ongchin J; Willis LM; Greenberg AS; Eng JM; Crawford JM; Murphy GF; Yagita H; Walczak H; Peschon JJ; van den Brink MR
    Nat Med; 2002 Dec; 8(12):1433-7. PubMed ID: 12426560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
    Chao NJ
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
    Li Q; Nakadai A; Takeda K; Kawada T
    Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
    Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
    Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic pathways in haematopoietic stem-cell transplantation.
    van den Brink MR; Burakoff SJ
    Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
    Arancia G; Malorni W; Donelli G
    Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
    Kosiewicz MM; Alard P; Liang S; Clark SL
    Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
    Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
    Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
    Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
    Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways.
    Naji A; Durrbach A; Carosella ED; Rouas-Freiss N
    Hum Immunol; 2007 Apr; 68(4):233-9. PubMed ID: 17400057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.